Therefore, for patients with resected stage III or stage IV melanoma, current systemic adjuvant therapy options include ICI therapy with pembrolizumab or nivolumab and targeted therapy with a dabrafenib–trametinib combination (for BRAF mutant melanoma). The gene discussed is BRAF; the disease is melanoma.